{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:55:44Z","timestamp":1791658544164,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000765","name":"UCL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jaip.2024.01.019","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T08:53:02Z","timestamp":1705827182000},"page":"1139-1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["What a Clinician Needs to Know About Genome Editing: Status and Opportunities for Inborn Errors of Immunity"],"prefix":"10.1016","volume":"12","author":[{"given":"Anne C.A.","family":"Mudde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Y.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.01.019_bib1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","article-title":"Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain","volume":"93","author":"Kim","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2024.01.019_bib2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nbt1125","article-title":"Gene targeting using zinc finger nucleases","volume":"23","author":"Porteus","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaip.2024.01.019_bib3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jaip.2024.01.019_bib4","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1126\/science.1204094","article-title":"TAL effectors: customizable proteins for DNA targeting","volume":"333","author":"Bogdanove","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jaip.2024.01.019_bib5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A\u00a0programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jaip.2024.01.019_bib6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib7","first-page":"e91","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"Reply. N Engl J Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2024.01.019_bib10","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","article-title":"CRISPR\/Cas9-mediated CCR5 ablation in human hematopoietic stem\/progenitor cells confers HIV-1 resistance in\u00a0vivo","volume":"25","author":"Xu","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.792684","article-title":"The CCR5 gene edited CD34(+)CD90(+) hematopoietic stem cell population serves as an optimal graft source for HIV gene therapy","volume":"13","author":"Karuppusamy","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.32","article-title":"Severe congenital neutropenias","volume":"3","author":"Skokowa","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2024.01.019_bib14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3324\/haematol.2019.221804","article-title":"CRISPR\/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients","volume":"105","author":"Nasri","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2024.01.019_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2024.01.019_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.stem.2015.02.005","article-title":"Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs","volume":"16","author":"Menon","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jaip.2024.01.019_bib18","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41467-019-09614-y","article-title":"Gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2024.01.019_bib19","article-title":"CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells","volume":"13","author":"Brault","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ymthe.2018.02.028","article-title":"Nuclease-free adeno-associated virus-mediated Il2rg gene editing in X-SCID mice","volume":"26","author":"Hiramoto","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2023.02.014","article-title":"An improved medium formulation for efficient ex\u00a0vivo gene editing, expansion and engraftment of hematopoietic stem and progenitor cells","volume":"29","author":"Rai","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jaip.2024.01.019_bib22","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.2020008503","article-title":"Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem\/progenitor cells","volume":"137","author":"De Ravin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2024.01.019_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108093","article-title":"Controlled cycling and quiescence enables efficient HDR in engraftment-enriched adult hematopoietic stem and progenitor cells","volume":"32","author":"Shin","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaip.2024.01.019_bib24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41587-020-0551-y","article-title":"Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking","volume":"38","author":"Ferrari","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaip.2024.01.019_bib25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib26","unstructured":"Pai S. Universal survival and superior immune reconstitution after lentiviral gene therapy with low dose conditioning for X-linked SCID (SCID-X1). Presented at: ASGCT 2023 Annual Meeting; May 16-20; Los Angeles, California."},{"key":"10.1016\/j.jaip.2024.01.019_bib27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10875-021-00989-6","article-title":"Gene editing rescues in\u00a0vitro T cell development of RAG2-deficient induced pluripotent stem cells in an artificial thymic organoid system","volume":"41","author":"Gardner","year":"2021","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtn.2022.12.006","article-title":"Multiplex HDR for disease and correction modeling of SCID by CRISPR genome editing in human HSPCs","volume":"31","author":"Iancu","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jaip.2024.01.019_bib29","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaci.2016.07.039","article-title":"Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation","volume":"139","author":"de la Morena","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/3233","article-title":"Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice","volume":"4","author":"Brown","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib31","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/sj.cgt.7700232","article-title":"Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome","volume":"7","author":"Sacco","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/gt.2010.144","article-title":"A\u00a0tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences","volume":"18","author":"Romero","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib33","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2015-11-683235","article-title":"Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome","volume":"127","author":"Hubbard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2024.01.019_bib34","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.celrep.2018.04.103","article-title":"Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome","volume":"23","author":"Kuo","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaip.2024.01.019_bib35","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013545","article-title":"Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome","volume":"13","author":"Vavassori","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15689-8","article-title":"Ectopic FOXP3 expression preserves primitive features of human hematopoietic stem cells while impairing functional T cell differentiation","volume":"7","author":"Santoni de Sio","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2024.01.019_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2018.12.003","article-title":"Lentiviral gene therapy in HSCs restores lineage-specific Foxp3 expression and suppresses autoimmunity in a mouse model of IPEX syndrome","volume":"24","author":"Masiuk","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jaip.2024.01.019_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz0571","article-title":"CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells","volume":"6","author":"Goodwin","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.jaip.2024.01.019_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10875-017-0453-z","article-title":"Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome","volume":"38","author":"Candotti","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2020.06.018","article-title":"Gene therapy for Wiskott-Aldrich syndrome: history, new vectors, future directions","volume":"146","author":"Ferrua","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib42","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1182\/blood-2019-124665","article-title":"Lentiviral hematopoietic stem and progenitor cell gene therapy for Wiskott-Aldrich syndrome (WAS): up to 8 years of follow up in 17 subjects treated since 2010","volume":"134","author":"Ferrua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2024.01.019_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","article-title":"Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome","volume":"28","author":"Magnani","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib44","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1182\/blood-2019-126161","article-title":"Outcome of hematopoietic stem cell gene therapy for Wiskott-Aldirch syndrome","volume":"134","author":"Labrosse","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2024.01.019_bib45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/hum.2017.047","article-title":"Comparison of zinc finger nucleases versus CRISPR-specific nucleases for genome editing of the Wiskott-Aldrich syndrome locus","volume":"29","author":"Gutierrez-Guerrero","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.stemcr.2016.06.003","article-title":"Gene correction of iPSCs from a Wiskott-Aldrich syndrome patient normalizes the lymphoid developmental and functional defects","volume":"7","author":"Laskowski","year":"2016","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jaip.2024.01.019_bib47","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1038\/s41467-020-17626-2","article-title":"Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich syndrome","volume":"11","author":"Rai","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2024.01.019_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.604371","article-title":"Baboon envelope pseudotyped \u201cNanoblades\u201d carrying Cas9\/gRNA complexes allow efficient genome editing in human T, B, and CD34(+) cells and knock-in of AAV6-encoded donor DNA in CD34(+) cells","volume":"3","author":"Gutierrez-Guerrero","year":"2021","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.jaip.2024.01.019_bib49","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s40265-018-1003-6","article-title":"Targeting Bruton\u2019s tyrosine kinase across B-cell malignancies","volume":"78","author":"da Cunha-Bang","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2024.01.019_bib50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.omtm.2021.01.007","article-title":"Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector","volume":"20","author":"Seymour","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jaip.2024.01.019_bib51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/mt.2010.259","article-title":"Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders","volume":"19","author":"Sather","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib52","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2010.140","article-title":"Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK","volume":"24","author":"Ng","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2024.01.019_bib53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/crispr.2020.0080","article-title":"Optimizing integration and expression of transgenic Bruton\u2019s tyrosine kinase for CRISPR-Cas9-mediated gene editing of X-linked agammaglobulinemia","volume":"4","author":"Gray","year":"2021","journal-title":"CRISPR J"},{"key":"10.1016\/j.jaip.2024.01.019_bib54","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ymthe.2020.08.004","article-title":"CRISPR-Cas9-mediated ELANE mutation correction in hematopoietic stem and progenitor cells to treat severe congenital neutropenia","volume":"28","author":"Tran","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jaip.2024.01.019_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn5811","article-title":"Therapeutic gene editing of T cells to correct CTLA-4 insufficiency","volume":"14","author":"Fox","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib57","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood-2012-07-445858","article-title":"SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease","volume":"121","author":"Rivat","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2024.01.019_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaci.2018.02.053","article-title":"Transfer of gene-corrected T cells corrects humoral and cytotoxic defects in patients with X-linked lymphoproliferative disease","volume":"142","author":"Panchal","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.828489","article-title":"Genome editing with TALEN, CRISPR-Cas9 and CRISPR-Cas12a in combination with AAV6 homology donor restores T cell function for XLP","volume":"4","author":"Houghton","year":"2022","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.jaip.2024.01.019_bib60","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood.2021011192","article-title":"CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes","volume":"138","author":"Brault","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2024.01.019_bib61","first-page":"3335","article-title":"Activated phosphoinositide 3-kinase delta syndrome 1: clinical and immunological data from an Italian cohort of patients","volume":"9","author":"Tessarin","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib62","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jaci.2018.06.039","article-title":"Primary immunodeficiency disorder caused by phosphoinositide 3-kinase delta deficiency","volume":"142","author":"Sogkas","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.01.019_bib63","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2018.208397","article-title":"Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase delta","volume":"104","author":"Swan","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2024.01.019_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101133","article-title":"Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction","volume":"31","author":"Poggi","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jaip.2024.01.019_bib65","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib66","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/1566523215666150515145255","article-title":"Successful combination of sequential gene therapy and rescue Allo-HSCT in two children with X-CGD\u2014importance of timing","volume":"15","author":"Siler","year":"2015","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2017.245","article-title":"Non-clinical efficacy and safety studies on G1XCGD, a lentiviral vector for ex\u00a0vivo gene therapy of X-linked chronic granulomatous disease","volume":"29","author":"Brendel","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.jaip.2024.01.019_bib70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ymthe.2016.11.012","article-title":"Targeted repair of CYBB in X-CGD iPSCs requires retention of intronic sequences for expression and functional correction","volume":"25","author":"Sweeney","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41434-021-00251-z","article-title":"Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR\/Cas9 with 53BP1 inhibition for enhanced homology-directed repair","volume":"28","author":"Sweeney","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nbt.3513","article-title":"Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease","volume":"34","author":"De Ravin","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaip.2024.01.019_bib74","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/hum.2019.194","article-title":"Differential transgene silencing of myeloid-specific promoters in the AAVS1 safe harbor locus of induced pluripotent stem cell-derived myeloid cells","volume":"31","author":"Klatt","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib75","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/bloodadvances.2016001214","article-title":"Gene-edited pseudogene resurrection corrects p47(phox)-deficient chronic granulomatous disease","volume":"1","author":"Merling","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2024.01.019_bib76","doi-asserted-by":"crossref","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","article-title":"Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells","volume":"8","author":"DeWitt","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104374","article-title":"High-level correction of the sickle mutation is amplified in\u00a0vivo during erythroid differentiation","volume":"25","author":"Magis","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.jaip.2024.01.019_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3480","article-title":"CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease","volume":"9","author":"De Ravin","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2024.01.019_bib79","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2217T to G\u2217C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2024.01.019_bib80","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2024.01.019_bib81","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cell.2023.02.027","article-title":"Human T cell generation is restored in CD3delta severe combined immunodeficiency through adenine base editing","volume":"186","author":"McAuley","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2024.01.019_bib82","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"4 Suppl 1","key":"10.1016\/j.jaip.2024.01.019_bib83","first-page":"55","article-title":"Prime editing of human CD34+ long-term hematopoietic stem cells precisely corrects the causative mutation of p47phox chronic granulomatous disease and restores NADPH oxidase activity in myeloid progeny","volume":"31","author":"Gori","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2024.01.019_bib84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41587-022-01600-y","article-title":"Novel recombinases for large DNA insertions","volume":"41","author":"Lampe","year":"2023","journal-title":"Nat Biotechnol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T08:28:46Z","timestamp":1728894526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2213219824000710"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.01.019","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What a Clinician Needs to Know About Genome Editing: Status and Opportunities for Inborn Errors of Immunity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}